Shire PLC (LON:SHP)‘s stock had its “conviction-buy” rating reiterated by equities research analysts at Goldman Sachs Group Inc. in a research note issued on Friday. They currently have a GBX 6,300 ($78.04) target price on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price target would indicate a potential upside of 23.94% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. HSBC dropped their price target on Shire PLC from GBX 5,250 ($65.03) to GBX 5,200 ($64.41) and set a ” hold” rating on the stock in a research note on Wednesday, September 28th. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research note on Friday, August 12th. Jefferies Group raised their price objective on Shire PLC from GBX 6,050 ($74.94) to GBX 6,600 ($81.75) and gave the stock a “buy” rating in a research report on Wednesday, August 3rd. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Finally, Deutsche Bank AG restated a “buy” rating and set a GBX 6,000 ($74.32) price objective on shares of Shire PLC in a research report on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Shire PLC presently has an average rating of “Buy” and an average target price of GBX 5,992.27 ($74.23).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) opened at 4898.50 on Friday. Shire PLC has a 12 month low of GBX 2,707.19 and a 12 month high of GBX 5,562.83. The firm has a 50-day moving average of GBX 4,980.23 and a 200 day moving average of GBX 4,690.21. The firm’s market cap is GBX 44.10 billion.

In related news, insider Dominic Blakemore bought 133 shares of Shire PLC stock in a transaction that occurred on Friday, September 30th. The stock was purchased at an average cost of GBX 5,010 ($62.06) per share, for a total transaction of £6,663.30 ($8,253.81).

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.